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Introduction {#sec1.1}
------------

It is estimated that 15% of the world\'s population has some degree of hearing loss (WHO, <https://www.who.int/pbd/deafness/estimates/en/>). In the US, approximately 35% of individuals over the age of 40 years have balance dysfunction and the prevalence increases with age ([@bib2]). Hearing loss and vestibular disorders can stem from various causes, including genetic defects, environmental exposures, aging, and ototoxic medications. The inner ear is composed of the cochlea and vestibular organs (utricle, saccule, and three semicircular canals) and each harbors mechanosensory hair cells that convert mechanical stimuli (i.e., sound or head motion) into electrical signals in afferent sensory neurons through synaptic transmission. These electrical signals in the vestibulocochlear nerve are then transmitted to the brainstem and subsequently the auditory cortex in the brain. Injury to the sensory hair cells, the vestibulocochlear nerve, or the synaptic connections between them can result in hearing loss and/or vertigo. The lack of meaningful regenerative capacity of the inner ear sensory cells of mammals means loss of function is permanent.

Extensive studies using animal models (e.g., frog, zebrafish, birds, and mammals) have advanced our knowledge of the human inner ear function and disease. Access to human inner ear tissues is severely limited since tissue sampling is technically challenging and leads to irreparable damage. Non-invasive clinical imaging techniques, such as computed tomography or MRI, currently do not provide sufficient resolution to determine most pathologies of the inner ear ([@bib36]). Pathologies of many human inner ear disorders can currently only be acquired by postmortem examinations.

In addition, access to inner ear tissues in mammalian animal models is also limited, which has slowed progress in the field. The sensory structures of the mammalian inner ear are surrounded by rigid bone and opening this rigid bone can lead to damage of the delicate cellular structures. In addition, cochlear explant cultures from mice are only technically feasible before postnatal day 7 (P7) ([@bib61]) and cannot be maintained for longer than 2 weeks ([@bib67], [@bib82]). Although other animal models (e.g., zebrafish) have more accessible hair cells, there are significant innate differences between non-mammalian vertebrate and mammalian models, such as the capacity for spontaneous hair cell regeneration ([@bib38], [@bib93]). To overcome these limitations associated with the current animal models, alternative model systems that are sustainable, easily accessible, and easily manipulated in the laboratory are needed for furthering our understanding of the inner ear biology and pathology.

Over the past few decades, stem cell biology has accelerated research into the pathologic mechanisms of Parkinson disease and cardiac tissue regeneration ([@bib3], [@bib34]). Currently, the mature mammalian cochlea completely lacks the capacity to spontaneously proliferate or regenerate hair cells and there is very limited regeneration potential in the vestibular system ([@bib19], [@bib94]). Activation of quiescent progenitor cells residing in the sensory epithelium of the inner ear or replacing missing hair cells with new hair cells derived from pluripotent stem cells (PSCs) could be a potential cure. Despite the identification of multipotent cell populations in the human fetal cochlea and in the adult human spiral ganglion, no proliferative cell populations with the capacity to give rise to hair cells have been reported in adult humans ([@bib78]).

Scientists have successfully derived inner ear progenitors and inner ear sensory cells from both multipotent and PSCs. Multipotent stem cells (i.e., somatic stem cells) exhibit limited self-renewal capacity and can differentiate only into cell types within an organ in which those stem cells reside. In contrast, PSCs (embryonic stem cells \[ESCs\] and induced pluripotent stem cells \[iPSCs\]) have infinite self-renewal capacity and the ability to differentiate into any cell type of the three major germ layers. Somatic stem cells, such as mesenchymal stem cells and neural stem cells, have been used to generate inner ear progenitors and restore damaged spiral ganglia ([@bib4], [@bib53], [@bib95]). However, there are a limited number of sources for these somatic stem cells and they exhibit a restricted capacity for differentiation ([@bib11]). On the contrary, PSCs are relatively easy to be maintained in culture and can differentiate into essentially any cell types ([@bib74], [@bib96]). Furthermore, genetically reprogramed iPSCs ([@bib85], [@bib86]) offer unique opportunities for personalized medicine, because the iPSCs can be derived from patients\' own cells and they are resistant to immunocompatibility issues ([@bib34], [@bib96]).

Here, we review the progress of *in vitro* derivation of PSC-derived inner ear hair cells, neurons, and organoids ([Figure 1](#fig1){ref-type="fig"}). We highlight the use of these PSC-derived tissues to understand the mechanisms of inner ear diseases and to restore inner ear function in early therapeutic trials ([Figure 1](#fig1){ref-type="fig"}).Figure 1Applications of PSCs in the Inner EarMouse- and human-derived ESCs and iPSCs can be induced to form otic epithelial progenitors (OEPs), hair cells, sensory neurons, and 3D organoids, which have scientific and therapeutic applications. ONP, otic neural progenitor.

Derivation of Inner Ear Tissues from PSCs {#sec1.2}
-----------------------------------------

Understanding the complex sequence of transcriptional changes and signaling pathways that underlie *in vivo* inner ear development is critical to the successful differentiation of PSCs into inner ear tissues, such as hair cells, supporting cells, and neurons *in vitro* ([@bib15], [@bib72]).

### Hair Cells and Sensory Epithelia {#sec1.2.1}

Numerous induction protocols have been developed to differentiate PSCs into hair cell-like cells ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}). Many of these protocols start with the generation of floating embryoid bodies (i.e., aggregated cell masses) followed by stepwise treatments of a combination of small molecules and/or recombinant proteins that become adhesive 2D cultures after approximately 5 days ([@bib1], [@bib47], [@bib64], [@bib65], [@bib73]). Other protocols are carried out entirely in 2D culture, which can provide a homogeneous cell population ([@bib8], [@bib17], [@bib43], [@bib62]). In contrast, 3D organoid systems contain multiple cell types and more precisely recapitulate *in vivo* composition of an organ. In 2013, the first 3D inner ear organoid system was developed using mESCs ([Figure 3](#fig3){ref-type="fig"}) ([@bib39]).Figure 2Hair Cell-like Cells Derived from PSCsSummary of induction strategies and characterization of both mouse and human PSC-derived hair cell-like cells. Petri dishes reflect adhesive 2D cnuultures, cell aggregates represent 3D floating cultures, and capsules represent rotary cultures. Characterization method highlighted in orange, key molecular markers (percentage of cells expressing) and mechanosensitivity are indicated. EB, embryonic body; d, day in culture; KOSR, knockout serum replacement; RA, retinoic acid.Figure 3Organoids Derived from PSCsSummary of induction strategies and characterization of both mouse and human PSC-derived organoids. Cell aggregates represent 3D floating cultures. Characterization method highlighted in orange, key molecular markers (percentage of cells expressing) and mechanosensitivity are indicated. ABR, auditory brainstem response; d, culture day; EB, embryonic body; RA, retinoic acid.

The initial steps of inner ear development require the formation of the ectodermal germ layer followed by formation of the pre-placodal ectoderm (PPE). Protocols first inhibit transforming growth factor β and WNT signaling and activate BMP to promote non-neural ectodermal development, while reducing mesoderm development ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) ([@bib1], [@bib39], [@bib40], [@bib43], [@bib64], [@bib73]). Insulin-like growth factor 1 promotes the fate of the anterior ectoderm, where the PPE emerges ([Figure 2](#fig2){ref-type="fig"}) ([@bib47], [@bib73]). The PPE gives rise to most of the cranial placodes, including the otic placode. Fibroblast growth factor (FGF) signaling (FGF3/10 in mouse) is the main inducer of the posterior domain of the PPE that gives rise to otic placode. WNT activation along with FGF signaling facilitates otic placode induction ([@bib81]) ([Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}).

Physical environmental cues provided by extracellular matrices, such as Matrigel, improve the efficiency of differentiation, as well as the resulting cellular assemblage ([@bib33], [@bib39], [@bib40], [@bib52]). For example, addition of Matrigel in the 3D inner ear organoid systems established by [@bib39], [@bib40] facilitated formation of fluid-filled vesicles containing hair cells and supporting cell-like cells ([Figure 3](#fig3){ref-type="fig"}). However, vestibular tissue-like organoids derived from hPSCs using the rotary cell culture system form hair cell-like cells on the surface of the organoids ([Figure 2](#fig2){ref-type="fig"}) ([@bib52]). At present, detailed mechanisms as to how extracellular matrices influence cell differentiation and survival are still unclear.

Specific PSC-derived cells along the developmental otic lineage are verified via expression of molecular markers, morphological examinations, and/or electrophysiological measurements ([@bib8], [@bib40], [@bib47], [@bib64]). SIX1 and E-cadherin expression are used to identify cells within the PPE ([@bib62], [@bib89]). PAX8 and PAX2 mark the posterior PPE (i.e., otic-epibranchial placodal domain, [Figures 2](#fig2){ref-type="fig"} and [3](#fig3){ref-type="fig"}) and are used to identify the otic progenitor cells within PSC-derived inner ear tissues ([@bib8], [@bib33], [@bib43]). Induction of hair cells from the posterior PPE requires either endogenous WNT or supplementation with a WNT activator. Hair cell-like cells are verified by the expression of BRN3C (also known as POU4F3), MYO7A, and ATOH1 ([@bib1], [@bib39], [@bib40], [@bib64]). Because native hair cells exhibit unique mechanosensitivity, patch-clamp recordings have been used to assess functional properties of PSC-derived hair cells. While the net potassium voltage gradient is most commonly recorded ([@bib8], [@bib17], [@bib40]), only a few studies have successfully recorded mechanotransduction currents from PSC-derived hair cells by deflecting hair bundles ([@bib48], [@bib64]). To date, PSC-derived hair cell-like cells display molecular markers and electrophysiological properties of vestibular hair cells and not cochlear hair cells. Discovery of alternative small molecules or culture conditions to generate cochlear hair cells from PSCs is still needed.

Induction protocols require optimization across PSC lines and across species. For example, Jeong and colleagues adapted the protocol for mouse ESC inner ear organoid ([@bib39]) to generate inner ear organoids from human PSCs ([Figure 3](#fig3){ref-type="fig"}) ([@bib33]). Temporal and spatial differences in gene expression across PSC lines likely contributes to known variability and efficacy of hair cell generation. Future improvements will occur as we advance our understanding of hair cell development or culture conditions.

Supporting cells of the sensory epithelia play an active role in ion metabolism necessary for hair cell function. The connexin proteins are the most abundant gap junction proteins expressed in the supporting cells. Mutations in *GJB2*, which encodes connexin 26 (CX26), are the most common cause of autosomal recessive non-syndromic sensorineural hearing loss ([@bib37]). In mouse 3D inner ear organoids, removing day 4 treatments (i.e., inhibition of BMP and activation of FGF) leads to increased expression of CX26 in day 7 aggregates ([@bib22]). Co-culturing the isolated small vesicles from day 7 aggregates with mouse cochlear feeder cells in 2D conditions resulted in hemichannel formation that was disrupted in CX26-deficient cell lines ([@bib22]). This study highlights the use of PSCs to study otic supporting cells.

### Neurons and Glia {#sec1.2.2}

Early neural induction protocols from PSCs involved using stromal cells derived from skull bone marrow, which resulted in efficient dopaminergic neuron production ([@bib35], [@bib97]). These protocols have been modified to derive inner ear sensory neurons and glial cells from PSCs ([Figure 4](#fig4){ref-type="fig"}). For example, mESCs treated with retinoic acid (RA), basic FGF (bFGF), and BMP4 were shown to give rise to β-III tubulin^+^ and peripherin^+^ neurons ([@bib12], [@bib55]). However, many of the available protocols are tailored to generate dopaminergic neurons due to their role in neurodegenerative disorders, such as Parkinson disease ([@bib9]). In contrast, glutamate is the primary neurotransmitter for the synaptic transmission between hair cells and afferent sensory neurons within the inner ear ([@bib60]). Thus, the derivation of glutamatergic neurons was a key step for recapitulating afferent neural transmission in the inner ear. [@bib71] used a mESC line that transiently expressed *Neurog1* along with supplementation of brain-derived neurotrophic factor (BDNF) and glia cell line-derived neurotrophic factor to promote the differentiation of mESCs into glutamatergic neurons both *in vitro* and *in vivo*. Forced expression of *Tlx3*, a genetic switch capable of conferring a glutamatergic over a GABAergic transmitter phenotype, promotes the glutamatergic neuronal specification from mESCs ([@bib41]).Figure 4Sensory Neuron-like Cells Derived from PSCsSummary of induction strategies and characterization of mouse and human PSC-derived neuron-like cells. Petri dishes reflect adhesive 2D cultures and cell aggregates represent 3D floating cultures. Characterization method highlighted in orange and key molecular markers (percentage of cells expressing) are indicated. EB, embryonic body; d, culture day; RA, retinoic acid.

As with the sensory epithelia in general, inner ear sensory neurons are derived from the otic placode ([@bib83]). Therefore, some of the early induction steps for these sensory neurons were designed based on known developmental trajectories of the otic placode. Small molecules, such as FGFs, BMP, sonic hedgehog, and noggin are used to support neuronal outgrowth from the otic placode ([@bib25], [@bib51], [@bib54], [@bib56], [@bib68]). BDNF and NT3 provide critical trophic support for inner ear sensory neuron afferents *in vivo* ([@bib20]) and are also used to support survival and growth of PSC-derived neurons ([@bib51], [@bib68], [@bib80]). Peripherin (which is specifically expressed by type II spiral ganglion neurons \[[@bib30]\]), BRN3A (also known as POU4F1), and β-III tubulin are commonly used to verify the formation of neurons, with glutamate receptors and transporters subsequently exploited to confirm subtype-specific derivatives ([Figure 4](#fig4){ref-type="fig"}). However, not all ESC-derived neurons within the same protocol express the same markers. [@bib51] showed that ∼90% of neuron-like cells were peripherin^+^ and β-III tubulin^+^, but only ∼46% were BRN3A^+^. Alternatively, synaptic contacts and neural innervation between co-existing hair cell-like cells and sensory neuron-like cells will provide more convincing evidence as to the identity of the derived cells.

To more precisely recapitulate the peripheral neuro-circuitry *in vitro*, a model that contains both sensory epithelia and innervating neurons is needed. Currently, there are two systems that potentially generate both tissues simultaneously ([Figure 3](#fig3){ref-type="fig"}). Treatment of hESCs with FGF3 and FGF10 for 10--12 days in 2D culture gives rise to both otic epithelial progenitors (OEPs) and otic neural progenitors (ONPs), which can be distinguished based on their morphology ([@bib8]). Hair cell-like cells can be derived from OEP after the inhibition of Notch and supplementation with RA and epidermal growth factor ([@bib8], [@bib44]). Sensory neuron-like cells can be derived from ONPs using bFGF and sonic hedgehog followed by BDNF and NT3 supplementation ([@bib8]). Co-culture of these derived hair cells and sensory neurons results in formation of neural connections *in vitro* ([@bib5]). However, this method required separate induction protocols before the co-culture of derived hair cells and sensory neurons.

On the other hand, 3D inner ear organoids contain both sensory epithelia (hair cells and supporting cells) and sensory neuron-like cells ([Figure 3](#fig3){ref-type="fig"}) ([@bib33], [@bib39], [@bib40]). Furthermore, several studies have replicated these protocols ([@bib16], [@bib76]) and used the systems for different applications, such as electrophysiological studies and disease modeling ([@bib48], [@bib87]). Although further characterization of sensory neuron-like cells is still in need, the inner ear organoid system provides a powerful tool to study peripheral sensory neural networks in the inner ear *in vitro*. Human inner ear organoids derived from hPSCs also offer the opportunity to explore developmental biology of the human inner ear and understand the differences that exist between mice and human inner ear development.

Stem Cell Therapy {#sec1.3}
-----------------

Cell-based therapy aims at replacing lost or damaged tissues via engraftment of viable transplanted cells or via stimulation of endogenous self-healing pathways by trophic factors ([@bib32]). Recent advances in stem cell engineering have made it possible to use cell-based therapy in combatting disorders, such as cancer, cardiovascular disease, and neurodegeneration ([@bib10], [@bib24], [@bib91]). Because mechanosensory hair cells and their associated neurons in the mammalian inner ears lack the capacity for regeneration ([@bib42]), cell-based therapy may offer a viable treatment option for inner ear disorders. Current challenges for cellular transplantation include cell survival and differentiation after transplantation, particularly in the scala media of the cochlea, which contains high potassium endolymph. In addition, proper arrangement of nascent sensory cells is critical since engraftment of supernumerary hair cells in the cochlea does not restore function ([@bib7]). The challenges to neuronal transplantation include establishing synaptic connections with both the inner ear sensory cells and the brainstem.

### Transplantation of Undifferentiated Stem Cells {#sec1.3.1}

Cellular transplantation of undifferentiated mESCs were initially tested by injecting them directly into the healthy rat cochlea ([@bib29]). Migration of transplanted cells along the auditory nerve toward the brain stem was detected, yet only ∼1% of the transplanted cells survived ([@bib29]). When using animals with injured vestibulocochlear nerves, the survival rate of implanted mESCs increased to over 60% 2 weeks after injection, but the survival rate drastically decreased to 25% 4 weeks after injection ([@bib70]). During transplantation, the use of BDNF improved the survival of donor cells and promoted the neural differentiation, while the use of the extracellular matrix enzyme ChABC (chondroitinase ABC enzyme) improves donor cell migration ([@bib66]).

Most transplanted cells have been detected in the perilymph spaces ([@bib45], [@bib70]), while a far lower percentage localized to the endolymph, where the sensory epithelia reside ([@bib45]). While the majority of transplantation studies were carried out via intra-cochlear sites, the feasibility of injecting mESCs into the utricle was tested and a population of the injected mESCs traveled to the perilymph space, with observation of some cells in the vicinity of the cochlear sensory epithelia and spiral limbus ([@bib69]). When mESCs were injected into the modiolus of the cochlea via the scala tympani, transplanted cells were detected along the vestibulocochlear nerve toward the brainstem and in the endolymph compartment ([@bib66], [@bib98]). Collectively, the site of injection appears to determine the trajectory and final destination of the transplanted ESCs.

In addition to cell survival and engraftment, it is important to verify whether implanted PSCs can further differentiate into inner ear cell types. Sakamoto and colleagues injected EGFP reporter-tagged mESCs into adult mouse inner ears and after 4 weeks observed differentiation of the transplanted cells marked by E-cadherin and neural cell adhesion molecule, markers for the ectodermal lineage. Nevertheless, these transplanted cells did not differentiate further into hair cells or neurons ([@bib75]). Overall, many studies over the past 15 years have documented the engraftments of PSCs and improved the transplantation procedures. Despite this success, the restoration in hearing function has not yet been achieved using undifferentiated PSCs as donor cells ([@bib23]). In addition, the concern remains with transplantation of undifferentiated PSCs and the development of teratomas ([@bib46]).

### Transplantation of Partially Differentiated Progenitors {#sec1.3.2}

Transplantation of partially differentiated progenitors from PSCs could be safer and more efficacious since this approach is less likely to result in teratoma formation when compared with undifferentiated PSCs ([@bib5], [@bib21]) and is more likely to generate terminally differentiated hair cells or neurons.

Neural progenitors derived from mESCs were first tested in mouse cochleae where the transplanted progenitor cells survived and underwent differentiation ([@bib14], [@bib63]). Outgrowth of neurites from transplanted cells toward damaged sensory epithelia was observed, but restoration of function was not detected ([@bib13], [@bib14], [@bib63]). Synaptic connectivity between neurons and hair cells is critical for proper inner ear function. [@bib50] co-cultured ESC-derived neurons and cochlear explants and observed establishment of synaptic contacts with the inner hair cells *in vitro*. Similar re-integration between differentiated neurons and native hair cells was confirmed using iPSC-derived progenitors ([@bib57]).

Many of the aforementioned early studies used the "stroma cell-derived inducing activity" protocol, which was originally developed for the induction of dopaminergic neurons ([@bib35]), to derive neural progenitors before transplantation to the inner ear ([@bib50], [@bib63], [@bib75]). The lack of glutamatergic phenotype may explain the failed recovery of function in these studies even though the synaptic connections were re-formed. More recently, neural induction of iPSCs in a 3D collagen matrix followed by transplantation into the scala tympani of the guinea-pig cochleae resulted in glutamate transporter (VGlut1) expression in \>50% of the transplanted neurons, yet only ∼2% of cells survived 2 weeks post-transplantation ([@bib31]).

Transplantation of hESC-derived ONPs into gerbils with selective loss of spiral ganglion neurons has led to improvement in the auditory brainstem response 10 weeks after transplantation. Neural cell bodies with processes extending to both cochlear hair cells and the cochlear nucleus of the brainstem were observed ([@bib8]). Human iPSC-derived OEPs have been injected into the modiolus of gerbil cochleae and the migration, engraftment, and differentiation of transplanted progenitor cells have been observed ([@bib5], [@bib49]). Furthermore, immunosuppression with cyclosporine improved the quantity of engrafted cells that migrated beyond the basilar membrane toward the scala media ([@bib49]). However, these transplanted cells still failed to differentiate into hair cells ([@bib5]).

In summary, when compared with undifferentiated PCSs, partially differentiated progenitors show more promising capacity for further differentiation, migration, and engraftment after transplantation and the risk of teratomas appears to be lower ([@bib58]). Despite the fact that restoration of auditory function has not been consistently realized, significant progress has been made with inner ear transplantation methodologies and survival of transplanted cells. Further studies to understand how to tonotopically organize transplanted cells, the mechanistic role of extracellular matrix components in cell survival, and the presence and proliferation of progenitor populations within the inner ear are needed to realize stem cell therapy within the auditory and vestibular system.

Modeling Inner Ear Disorders with PSCs {#sec1.4}
--------------------------------------

Modeling human inner ear disorders has relied heavily on insights obtained from rodent models ([@bib59], [@bib84], [@bib92]). In addition, the use of mammalian cochlear explants are generally limited to neonatal mice due to the aforementioned technical difficulties associated with inner ear tissues at later developmental ages ([@bib61]). Another limiting factor with primary cochlear explants is that cultures cannot be maintained for longer than ∼14 days ([@bib67], [@bib82]). In contrast, inner ear tissues generated from human and mouse PSCs can be maintained for many weeks under proper culture conditions. Furthermore, patient-specific, disease-associated mutations can be introduced in the genome of PSCs using CRISPR/Cas9 genome editing technology to study the molecular mechanisms of genetic hearing loss.

Hundreds of genetic mutations are associated with hearing loss, yet the specific mechanisms of deafness are unknown for most genes. *Barhl1* is homeobox gene expressed in hair cells and important for hair cell maintenance. Constitutive expression of mutant *Barhl1* in mESC-derived hair cells disrupts the derivation of hair cells *without* altering the induction of early otic progenitors ([@bib99]). It should be noted that the mESCs were co-cultured with utricular stromal cells, which can result in high variability across cultures. Subsequent RNA sequencing (RNA-seq) analysis revealed that the integrity of the 3′ enhancer region of *Barh1* contains a plausible binding site for ATOH1 and is critical for proper hair cell differentiation ([@bib28]) ([Figure 5](#fig5){ref-type="fig"}).Figure 5PSCs in Inner Ear Disease ModelingHuman and mouse ESCs and iPSCs in combination with genomic editing technologies (e.g., CRISPR/Cas9), provide powerful tools for investigating disease mechanisms.

In lieu of the 2D culture system, mESC-derived inner ear 3D organoids have been used to study hair cell degeneration resulting from defective *Tmprss3* ([Figure 5](#fig5){ref-type="fig"}). The type II transmembrane serine protease, TMPRSS3, is required for maintenance of hair cells in mice and as nonsense mutation (*Tmprss3*^*Y260X*^) leads to rapid hair cell degeneration at P12 in mice ([@bib18]). Mutations in *TMPRSS3* cause congenital or early-onset hearing loss in humans ([@bib77]), yet the functional role of TMPRSS3 in the inner ear is not fully understood. ESC-derived organoids from *Tmprss3*^*Y260X*^ mice show normal hair cell development followed by hair cell degeneration at differentiation day 38 (equivalent to ∼P14 in mouse) ([@bib87]). These observations are comparable with phenotypes observed in *Tmprss3*^*Y260X*^ mice. Furthermore, hair cells derived from CRISPR/Cas9-generated *Tmprss3* knockout (KO) mESCs showed more severe degeneration than those derived from *Tmprss3*^*Y260X*^ mESCs ([Figure 5](#fig5){ref-type="fig"}). These results demonstrate that the extent of degeneration varies across type of mutations (KO versus truncation). The potential roles of TMPRSS3, including the maintenance of intracellular ion homeostasis and extracellular matrix organization, in hair cells were inferred by differential gene expression analyses using single-cell RNA-seq (scRNA-seq) between wild-type and *Tmprss3*-KO organoid hair cells ([@bib87]). Together, this work highlights the utility of PSC-derived organoid systems for investigating the molecular mechanisms underlying genetic inner ear disorders and will be vital for confronting the high levels of genetic heterogeneity that have hindered our understanding of the link between genetic mutations and hearing loss ([@bib90]).

In addition to recapitulating inner ear pathology caused by genetic mutations, PSCs are also a powerful tool for examining the effects of "genetic correction" in gene therapy. Mutations in *MYO7A* and *MYO1*5A are known human deafness genes ([@bib79]). Hair cells derived from patient-specific iPSC lines carrying *MYO7A* and *MYO1*5A mutations harbor abnormal stereocilia ([@bib6], [@bib88]). After correction of genetic mutations using CRISPR/Cas9 technology, derived hair cells showed restored structure of stereocilia-like protrusions and voltage-dependent currents and current densities similar to controls ([Figure 5](#fig5){ref-type="fig"}) ([@bib6], [@bib88]).

As an alternative to CRISPR-edited PSCs, patient-derived iPSCs offer personalized human models for studying genetic-associated inner ear disorders. iPSCs derived from Pendred syndrome patients with biallelic *SLC26A4* point mutations have provided novel insights into how pendrin protein dysfunction leads to hearing loss ([Figure 5](#fig5){ref-type="fig"}) ([@bib26], [@bib27]). Pendrin is an anion exchange protein encoded by the gene *SLC26A4* and a primary cause of hair cell dysfunction was believed to stem from defects in anion exchange ([@bib26]). Outer sulcus cells generated from these SLC26A4 mutant iPSCs demonstrated aggregated mutant pendrin proteins within the cytoplasm and exhibited decreased survival in response to cell stress induced with proteasome inhibition. These data suggest that hair cell dysfunction in Pendred syndrome may result from aggregation of mutant pendrin protein that results in susceptibility of cells to stress and cell death. Furthermore, by testing patient-derived iPSCs, they demonstrated that treatment with rapamycin, an autophagy activator, increases cell survival and may attenuate the progression of hearing loss in patients with Pendred syndrome ([Figure 5](#fig5){ref-type="fig"}) ([@bib26], [@bib27]).

In summary, PSC-derived *in vitro* inner ear models offer valuable tools for elucidating mutant genotype-associated phenotypes, examining the effects of gene correction, and investigating the molecular mechanisms underlying the pathologies.

Conclusions and Future Perspectives {#sec1.5}
-----------------------------------

Significant progress has been made over the past 15 years in applications of PSCs in inner ear therapies. Inner ear hair cells, supporting cells, and neurons can now be generated from both mouse and human PSCs, although reproducibility and scalability still pose challenges. Better understandings of inner ear development and incorporation of such knowledge into the induction protocols will greatly improve efficiency and reproducibility. PSC-derived otic progenitors have shown the capacity for differentiation, migration, and engraftment with native tissues after transplantation in rodent models ([Figure 5](#fig5){ref-type="fig"}). However, there remains the risk of the formation of teratomas. Reduction of this potential side effect has been demonstrated using partially differentiated PSCs, yet discovery of novel methods to regulate off target differentiation *in vivo* is needed.

PSC-derived inner ear tissues, especially those from patient-specific iPSCs, provide powerful tools for unveiling disease mechanisms that were previously difficult, if not impossible, to examine. Stem cell-derived inner ear organoids along with scRNA-seq can provides mechanistic insights into genetic deafness ([Figure 5](#fig5){ref-type="fig"}). Human PSC-based organoid studies *in vitro* may be directly translatable to patients *in vivo*. Current limitations to the use of PSCs to study and treat inner ear disorders include labor-intensive culture protocols, variable efficiency of tissue derivation, inability to derive cochlear tissues in 3D organoids, limited differentiation and integration in host tissues, and inability to study age-related disorders. Opportunities for future translation in the field lie in optimization of gene therapies, personalized cell transplantation therapeutics, and drug screening for hair cell regeneration or ototoxicity.
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